The prognostic value of serum erythropoietin in patients with lower-risk myelodysplastic syndromes: a review of the literature and expert opinion
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1432-0584
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
The prognostic value of serum erythropoietin in patients with lower-risk myelodysplastic syndromes: a review of the literature and expert opinion ; volume:99 ; number:1 ; day:25 ; month:10 ; year:2019 ; pages:7-19 ; date:1.2020
Annals of hematology ; 99, Heft 1 (25.10.2019), 7-19, 1.2020
- Creator
-
Park, Sophie
Kelaidi, Charikleia
Meunier, Mathieu
Casadevall, Nicole
Gerds, Aaron T.
Platzbecker, Uwe
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s00277-019-03799-4
- URN
-
urn:nbn:de:101:1-2020042304052850307178
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:49 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Park, Sophie
- Kelaidi, Charikleia
- Meunier, Mathieu
- Casadevall, Nicole
- Gerds, Aaron T.
- Platzbecker, Uwe
- SpringerLink (Online service)
Other Objects (12)
Tierexperimentelle Untersuchungen zur Resorbierbarkeit von drei neuentwickelten porösen Biogläsern, Bioglaskeramiken
Correction to: The prognostic value of serum erythropoietin in patients with lower-risk myelodysplastic syndromes: a review of the literature and expert opinion
Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes
Azacitidin : prophylaktische Maßnahmen und Therapiemanagement ; Nebenwirkungen erkennen, vermeiden, behandeln
Luspatercept mitigates bone loss driven by myelodysplastic neoplasms and estrogen-deficiency in mice
Myelodysplastic syndromes
Myelodysplastic syndromes
Immunprofil von Patienten mit fortgeschrittenen Myelodysplastischen Syndromen oder Akuten Myeloischen Leukämien unter der gegen CD123 gerichteten Therapie mit Talacotuzumab
Bone marrow mesenchymal stromal cell-derived extracellular matrix displays altered glycosaminoglycan structure and impaired functionality in Myelodysplastic Syndromes
Bone marrow mesenchymal stromal cell-derived extracellular matrix displays altered glycosaminoglycan structure and impaired functionality in Myelodysplastic Syndromes
Response to azacitidine is independent of p53 expression in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemia
Machine learning assisted real‑time deformability cytometry of CD34+ cells allows to identify patients with myelodysplastic syndromes
Tierexperimentelle Untersuchungen zur Resorbierbarkeit von drei neuentwickelten porösen Biogläsern, Bioglaskeramiken
Correction to: The prognostic value of serum erythropoietin in patients with lower-risk myelodysplastic syndromes: a review of the literature and expert opinion
Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes
Azacitidin : prophylaktische Maßnahmen und Therapiemanagement ; Nebenwirkungen erkennen, vermeiden, behandeln
Luspatercept mitigates bone loss driven by myelodysplastic neoplasms and estrogen-deficiency in mice
Myelodysplastic syndromes
Myelodysplastic syndromes
Immunprofil von Patienten mit fortgeschrittenen Myelodysplastischen Syndromen oder Akuten Myeloischen Leukämien unter der gegen CD123 gerichteten Therapie mit Talacotuzumab
Bone marrow mesenchymal stromal cell-derived extracellular matrix displays altered glycosaminoglycan structure and impaired functionality in Myelodysplastic Syndromes
Bone marrow mesenchymal stromal cell-derived extracellular matrix displays altered glycosaminoglycan structure and impaired functionality in Myelodysplastic Syndromes
Response to azacitidine is independent of p53 expression in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemia
Machine learning assisted real‑time deformability cytometry of CD34+ cells allows to identify patients with myelodysplastic syndromes
Tierexperimentelle Untersuchungen zur Resorbierbarkeit von drei neuentwickelten porösen Biogläsern, Bioglaskeramiken
Correction to: The prognostic value of serum erythropoietin in patients with lower-risk myelodysplastic syndromes: a review of the literature and expert opinion
Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes
Azacitidin : prophylaktische Maßnahmen und Therapiemanagement ; Nebenwirkungen erkennen, vermeiden, behandeln
Luspatercept mitigates bone loss driven by myelodysplastic neoplasms and estrogen-deficiency in mice
Myelodysplastic syndromes
Myelodysplastic syndromes
Immunprofil von Patienten mit fortgeschrittenen Myelodysplastischen Syndromen oder Akuten Myeloischen Leukämien unter der gegen CD123 gerichteten Therapie mit Talacotuzumab
Bone marrow mesenchymal stromal cell-derived extracellular matrix displays altered glycosaminoglycan structure and impaired functionality in Myelodysplastic Syndromes
Bone marrow mesenchymal stromal cell-derived extracellular matrix displays altered glycosaminoglycan structure and impaired functionality in Myelodysplastic Syndromes
Response to azacitidine is independent of p53 expression in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemia